Dopamine D2 and serotonin 5-HT2A receptors (antagonist)
Assets acting on this target.
- Class
- atypical antipsychotic
- Pathway
- postsynaptic dopamine D2 and serotonin 5-HT2A receptor antagonism in mesolimbic and mesocortical pathways
Dopamine D2 and serotonin 5-HT2A receptors are G-protein-coupled receptors that atypical antipsychotics block simultaneously. D2 receptors are the primary site through which excess dopaminergic signaling in mesolimbic brain circuits is thought to produce the positive symptoms of psychosis, such as hallucinations and delusions; antagonizing D2 dampens this overactive signaling. Older antipsychotics relied on D2 blockade alone, which is effective against positive symptoms but tends to cause movement disorders and elevated prolactin because dopamine pathways elsewhere in the brain are also affected. Adding antagonism of 5-HT2A receptors, which normally restrain dopamine release in some of these same circuits, partially offsets that dopamine reduction outside the mesolimbic pathway, lowering the risk of movement-related side effects while preserving antipsychotic benefit. This dual-receptor strategy defines the 'atypical' class and is used broadly across schizophrenia, bipolar disorder, and related psychotic or mood conditions where dopaminergic and serotonergic signaling are dysregulated. The specific balance between D2 and 5-HT2A affinity varies across individual agents, shaping differences in efficacy and tolerability, but the underlying rationale, dampening excessive dopaminergic drive while limiting collateral effects through serotonergic modulation, is shared across the class.
Related mechanisms
Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs compared
23 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Asenapine | AbbVie, Organon | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Clozapine | HLS Therapeutics Inc. | small molecule | Approved | Approved in Schizophrenia |
| Iloperidone (Fanapt)Fanapt | Vanda Pharmaceuticals | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Lurasidone | Angelini Pharma S.p.A. (A.C.R.A.F. S.p.A.), Sumitomo Pharma | small molecule | Approved | Approved in Bipolar Depression; Approved in Schizophrenia |
| Milsaperidone (VHX-896) | Vanda Pharmaceuticals | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia; Phase 3 in Major Depressive Disorder |
| Olanzapine (Zyprexa Relprevv)Zyprexa Relprevv | Cheplapharm Arzneimittel GmbH | small molecule | Approved | Approved in Schizophrenia |
| Olanzapine (Zyprexa)Zyprexa | Cheplapharm Arzneimittel GmbH, Eli Lilly | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Paliperidone (Invega)Invega | Johnson & Johnson | small molecule | Approved | Approved in Schizophrenia |
| Paliperidone palmitate (Erzofri)Erzofri | Luye Pharma Group | small molecule | Approved | Approved in Schizophrenia |
| Paliperidone palmitate (Invega Sustenna)Invega Sustenna | Johnson & Johnson | small molecule (palmitate ester prodrug, long-acting injectable suspension) | Approved | Approved in Schizophrenia |
| Paliperidone palmitate (Invega Trinza)Invega Trinza / Invega Hafyera | Johnson & Johnson | small molecule (palmitate ester prodrug, long-acting injectable suspension) | Approved | Approved in Schizophrenia |
| Perseris | Indivior Pharmaceuticals, Inc. | small molecule | Approved | Approved in Schizophrenia |
| Quetiapine (Seroquel XR)Seroquel XR | AstraZeneca, Cheplapharm Arzneimittel GmbH | small molecule | Approved | Approved in Bipolar Disorder; Approved in Major Depressive Disorder; Approved in Schizophrenia |
| Quetiapine (Seroquel)Seroquel | Cheplapharm Arzneimittel GmbH, Luye Pharma Group | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Risperidone (Risperdal Consta)Risperdal Consta | Johnson & Johnson | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Risperidone (Risperdal)Risperdal | Johnson & Johnson | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Risperidone (Rykindo)Rykindo | Luye Pharma Group | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Risperidone (Uzedy)Uzedy | Medincell, Teva Pharmaceutical Industries | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Ziprasidone | Viatris | small molecule | Approved | Approved in Bipolar Disorder; Approved in Schizophrenia |
| Loxapine (Adasuve)Adasuve | Ferrer Internacional, Lee's Pharmaceutical | small molecule | Phase 3 | Phase 3 in Bipolar Disorder; Phase 3 in Schizophrenia |
| Olanzapine/samidorphan (Qilu) | Qilu Pharmaceutical | small molecule combination | Phase 3 | Phase 3 in Schizophrenia |
| Risperidone (QUAR) | Laboratorios Farmacéuticos Rovi, S.A. | small molecule | Phase 1 | Phase 1 in Schizophrenia |
| Paliperidone palmitate (CSPC) | CSPC Pharmaceutical Group | small molecule (palmitate ester prodrug, long-acting injectable suspension); an independently-developed generic/biosimilar formulation, distinct from Janssen's Invega Trinza | Stage not recorded | Not recorded |